Abiopharma

🔍 Jejurikar Shailesh (Director)

Company: PROCTER & GAMBLE Co (PG)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Acquired 16,195 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: A | equity_swap_involved: 0 | shares_owned_after: 45,502.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: By Retirement Plan Trustee | shares_owned_after: 3,741.74
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: Sankhya S Jejurikar Revocable Trust | shares_owned_after: 19,757.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: Shailesh Jejurikar Trust | shares_owned_after: 35,836.00
• Acquired 45 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-17 | Code: A | equity_swap_involved: 0 | shares_owned_after: 734.27 | transaction_form_type: 5 | Footnotes: F3, F4, F4

Footnotes:

• F1: Stock award pursuant to issuer's 2025 Stock and Incentive Compensation Plan.
• F2: Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock.
• F3: Dividend equivalents in the form of Restricted Stock Units (RSUs) previously awarded pursuant to issuer's retirement program. All such RSUs represent a contingent right to receive Procter & Gamble common stock.
• F4: These units will deliver in shares on retirement from the company, unless delivery is deferred or such shares are contributed to reporting person's deferred compensation account.